USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Western European Companion Diagnostics Market
Western European Companion Diagnostics Market
Regulatory Hurdles and LDTs Stall the Global and European Market for Companion Diagnostics
RELEASE DATE
23-May-2014
23-May-2014
REGION
Asia Pacific
Asia Pacific
Research Code: NCF9-01-00-00-00
SKU: LS00116-AP-MR_16957
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
LS00116-AP-MR_16957
Description
The research service aims to give a global outlook of the companion diagnostic market landscape, with a specific focus on Western European countries. The segments related to oncology discussed in this study include breast cancer, lung cancer, colorectal cancer and other cancers, and non-oncology related infectious disease, CNS, and cardiovascular. The forecasts are based on test volumes for these cancers and disease types. Effective analysis of the reimbursement pathway in Germany, the United Kingdom, France, Italy, Spain, Scandinavia, and Benelux, coupled with regulatory approval in Europe, is discussed. A comparative assessment of regulatory scenarios has been performed to assess easy-target markets.
Table of Contents
Key Findings
Key Findings (continued)
Scope and Segmentation
Key Questions This Study Will Answer
Market Engineering Measurements
CEO’s Perspective
Key Companies to Watch
Executive Summary—3 Big Predictions
Market Background
Market Background (continued)
Market Background (continued)
Market Background (continued)
Market Segmentation
Overall Market Perspective
Defining Healthcare Trends in the Future
Regulatory Overview—Europe
Regulatory Overview—Europe (continued)
Future IVD Regulation in Europe
Role of EMA
Drug Labels Requiring Biomarker Testing by the EMA
Comparison of FDA and CE Marking
Comparative Analysis of the United States, Europe, and China
Global Regulatory Outlook
New Market Opportunities
New Market Opportunities (continued)
New Market Opportunities (continued)
Current Participant Strategies Discussion
Current Participant Strategies Discussion (continued)
Unmet Needs Discussion
Unmet Needs Discussion (continued)
Market Drivers
Market Restraints
Market Impact of Top Trends
Market Engineering Measurements
Snapshot of the European Companion Diagnostics Market
Important Market Characteristics
Forecast Assumptions
Total Companion Diagnostics Market—Revenue Forecast
Total Companion Diagnostics Market—Revenue Forecast by Disease Focus
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
PEST Analysis
PEST Analysis (continued)
Revenue Forecast for Breast Cancer Testing
Revenue Forecast for Breast Cancer Testing Discussion
Revenue Forecast for Lung Cancer Testing
Revenue Forecast for Lung Cancer Testing Discussion
Revenue Forecast for Colorectal Cancer Testing
Revenue Forecast for Other Cancers Testing
Revenue Forecast for Colorectal Cancer and Other Cancers Testing Discussion
Revenue Forecast for Infectious Disease, CNS, and Cardiovascular Testing
Revenue Forecast for Infectious Disease, CNS, and Cardiovascular Testing Discussion
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Competitive Environment
Competitive Environment (continued)
Product Analysis
Product Analysis (continued)
Top Competitors
Top Competitors (continued)
Market Share by Tier
Market Share by Tier (continued)
Merger, Acquisition, and Partnership Assessment
Merger, Acquisition, and Partnership Assessment (continued)
Companion Diagnostic Partners
Companion Diagnostic Partners (continued)
Therapy Areas for Companion Diagnostic Partnerships
Types of Companion Diagnostic Partnerships
Global Reach of Companion Diagnostic Partnership
Introduction
Reimbursement Systems Overview
CDx Penetration Across Western Europe
Germany—Personalized Medicine Overview
Germany—Personalized Medicine Overview (continued)
Germany—Overview of Reimbursement
France—Personalized Medicine Overview
France—Personalized Medicine Overview (continued)
France—Overview of Reimbursement
France—Overview of Reimbursement (continued)
The United Kingdom—Personalized Medicine Overview
The United Kingdom—Personalized Medicine Overview (continued)
The United Kingdom—Overview of Reimbursement
Italy—Personalized Medicine Overview
Italy—Personalized Medicine Overview (continued)
Italy—Personalized Medicine Overview (continued)
Italy—Overview of Reimbursement
Italy—Overview of Reimbursement (continued)
Spain—Personalized Medicine Overview
Spain—Healthcare Payment System
Spain—Pricing and Reimbursement
Spain—Pricing and Reimbursement (continued)
Scandinavia—Personalized Medicine Overview
Scandinavia—Personalized Medicine Overview (continued)
Scandinavia—Reimbursement Overview
Scandinavia—Reimbursement Overview (continued)
Benelux—Personalized Medicine Overview
The Netherlands—Personalized Medicine Overview
The Netherlands—Reimbursement Overview
The Netherlands—Reimbursement Overview (continued)
Belgium—Personalized Medicine Overview
Belgium—Reimbursement Overview
Belgium—Reimbursement Overview (continued)
The Last Word—3 Big Predictions
The Last Word—Discussion
The Last Word—Discussion (continued)
The Last Word—Discussion (continued)
The Last Word—Discussion (continued)
The Last Word—Discussion (continued)
Legal Disclaimer
Europe—Drivers Explained
Europe—Drivers Explained (continued)
Europe—Drivers Explained (continued)
Europe—Restraints Explained
Europe—Restraints Explained (continued)
Europe—Restraints Explained (continued)
Europe—Restraints Explained (continued)
Europe—Restraints Explained (continued)
Europe—Restraints Explained (continued)
Europe—Restraints Explained (continued)
Europe—Restraints Explained (continued)
Decision Support Database
Decision Support Database (continued)
Decision Support Database (continued)
Decision Support Database (continued)
Decision Support Database (continued)
Associated Multimedia
Market Engineering Methodology
Learn More—Next Steps
The global generics industry is in an interesting phase. Prescription volumes for generics are rising in the US and European markets, while regional manufacturers are struggling to meet demand. However, while Asian prescription volumes are lower than that of Western markets, Asian manufacturers are catering to domestic markets and exporting a significant percentage of products to the US and Europe. India, China, South Korea, and Japan are the important Asian markets. The generics industry has moved on after patent cliff, and is more focused on increasing product quality and market share. Overall, the global generics market will see an average growth in the next 2-3 years.
| No Index | No |
|---|---|
| Podcast | No |
| Author | Divyaa Ravishankar |
| WIP Number | NCF9-01-00-00-00 |
| Is Prebook | No |